ANALYSIS OF HEMATOLOGICAL PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: CONTRIBUTION TO PREVENTION OF AVOIDABLE HEMATOLOGICAL COMPLICATIONS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F22%3A00556113" target="_blank" >RIV/68081707:_____/22:00556113 - isvavai.cz</a>
Result on the web
<a href="https://www.excli.de/index.php/excli/article/view/4702" target="_blank" >https://www.excli.de/index.php/excli/article/view/4702</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.17179/excli2022-4702" target="_blank" >10.17179/excli2022-4702</a>
Alternative languages
Result language
angličtina
Original language name
ANALYSIS OF HEMATOLOGICAL PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: CONTRIBUTION TO PREVENTION OF AVOIDABLE HEMATOLOGICAL COMPLICATIONS
Original language description
Administration of biological therapy (BT) in rheumatoid arthritis (RA) patients is often associated with hemato-logical complications, which result in switching among therapies. Thus, there is an instant need for suitable screening parameters that will help to individualize the therapy and minimize the onset of adverse effects. We analyzed the hematological profile of 99 RA patients receiving TNF-alpha (Adalimumab ADA, Golimumab GOL, Etanercept ETA) or IL-6 receptor (Tocilizumab TCZ) inhibitors in order to find possible indicators to improve personalization of RA therapy. BTs significantly affect the levels of observed hematological parameters. In contrast to TNF-alpha inhibitors, TCZ normalized almost all monitored hematological parameters to values of healthy donors. Only GOL from the TNF-alpha inhibitors studied, was able to normalize neutrophil counts, as well as platelet indicators. Importantly, effects on the blood parameters (e.g. lymphocytes or platelet count) differ even within the same therapeutic group (anti-TNF alpha). Variable effects of individual biological agents in RA treatment point to importance to evaluate the patient's hematological profile to improve the selection of suitable BT. It will help to personalize the administration of BT and prevent unnecessary switching from an effective therapy just because of provocation of avoidable hematological complications.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EXCLI Journal
ISSN
1611-2156
e-ISSN
1611-2156
Volume of the periodical
21
Issue of the periodical within the volume
2022
Country of publishing house
DE - GERMANY
Number of pages
15
Pages from-to
580-594
UT code for WoS article
000766922900001
EID of the result in the Scopus database
2-s2.0-85126804245